Recro Pharma agrees to buy assets from Alkermes for $170m
The deal will see Recro Pharma secure worldwide rights to IV/IM meloxicam and also a contract manufacturing facility, royalty and formulation business in Gainesville, Georgia, US. IV/IM meloxicam
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.